Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice

Neuroscience

Volumn 124, Issue 4, 2004, Pages 725-733

  Sullivan, P M ^a   Mace, B E ^a   Maeda, N ^b   Schmechel, D E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

A ; AD; African green monkey; AGM; Alzheimer's disease; Amyloid ; Apo; APOE; Apolipoprotein (refers to the protein or isoform); Astrocytes; Brain regions; Gene targeted mice; Non human primates; Protein levels

Indexed keywords

APOLIPOPROTEIN E; BRAIN PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CERCOPITHECIDAE; CONTROLLED STUDY; FRONTAL CORTEX; GENE TARGETING; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INBRED STRAIN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WILD TYPE;

AGED; ALLELES; ANIMALS; APOLIPOPROTEINS E; BLOTTING, WESTERN; BRAIN; CERCOPITHECUS AETHIOPS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; NEUROGLIA; TISSUE DISTRIBUTION;

EID: 1542291105     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2003.10.011     Document Type: Article

References (63)

1. Ali S.M., Dunn E., Oostveen J.A., Hall E.D., Carter D.B. Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. Brain Res Mol Brain Res. 38:1996;37-44.
2. Aono M., Lee Y., Grant E.R., Zivin R.A., Pearlstein R.D., Warner D.S., Bennett E., Laskowitz D.T. Apolipoprotein E protects against NMDA excitotoxicity. Neurobiol Dis. 11:2002;214-220.
3. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 96:1999;15233-15238.
4. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 17:1997;263-264.
5. Beffert U., Danik M., Krzywkowski P., Ramassamy C., Berrada F., Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Brain Res. Rev. 27:1998;119-142.
6. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol Brain Res. 33:1995;174-178.
7. Bohnet K., Pillot T., Visvikis S., Sabolovic N., Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res. 37:1996;1316-1324.
8. Bowman B.H., Yang F., Buchanan J.M., Adrian G.S., Martinez A.O., Jansen L., Zhao M., Atherton S.L., Hixson J.E. Human APOE protein localized in brains of transgenic mice. Neurosci Lett. 219:1996;57-59.
9. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 76:1985;1501-1513.
10. Boyles J.K., Zoellner C.D., Anderson L.J., Kosik L.M., Pitas R.E., Weisgraber K.H., Hui D.Y., Mahley R.W., Gebicke-Haerter P.J., Ignatius M.J. A role for apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest. 83:1989;1015-1031.
11. Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R.E., Wyss-Coray T., Mucke L., Mahley R.W. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice isoform-specific effects on neurodegeneration. J Neurosci. 19:1999;4867-4880.
12. Corder E.H., Robertson K., Lannfelt L., Bogdanovic N., Eggertsen G., Wilkins J., Hall C. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med. 4:1998;1182-1184.
13. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C. Jr, Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E. Protective effect of apolipoprotein E type 2 allele for late ons et al. Alzheimer disease. Nat Gen. 7:1994;180-184.
14. de Chaves E.l, Rusinol A.E., Vance D.E., Campenot R.B., Vance J.E. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J Biol Chem. 272:1997;30766-30773.
15. Diedrich J.F., Minnigan H., Carp R.I., Whitaker J.N., Race R., Frey W.2nd, Haase A.T. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol. 65:1991;4759-4768.
16. Einstein G., Patel V., Bautista P., Kenna M., Melone L., Fader R., Karson K., Mann S., Saunders A.M., Hulette C., Mash D., Roses A.D., Schmechel D.E. Intraneuronal ApoE in human visual cortical areas reflects the staging of Alzheimer disease pathology. J Neuropathol Exp Neurol. 57:1998;1190-1201.
17. 3H]dopa in various regions of the brain. J Neurochem. 13:1966;655-669.
18. Grehan S., Tse E., Taylor J.M. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 21:2001;812-822.
19. Hallman D.M., Boerwinkle E., Saha N., Sandholzer C., Menzel H.J., Csazar A., Utermann G. The apolipoprotein E polymorphism a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 49:1991;338-349.
20. Hamanaka H., Katoh-Fukui Y., Suzuki K., Kobayashi M., Suzuki R., Motegi Y., Nakahara Y., Takeshita A., Kawai M., Ishiguro K., Yokoyama M., Fujita S.C. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum Mol Genet. 9:2000;353-361.
21. Han S.H., Einstein G., Weisgraber K.H., Strittmatter W.J., Saunders A.M., Pericak-Vance M., Roses A.D., Schmechel D.E. Apolipoprotein E is localized to the cytoplasm of human cortical neurons a light and electron microscopic study. Neuropathol Exp Neurol. 53:1994;535-544.
22. Han S.H., Hulette C., Saunders A.M., Einstein G., Pericak-Vance M., Strittmatter W.J., Roses A.D., Schmechel D.E. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol. 128:1994;13-26.
23. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 31:1990;545-548.
24. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 97:2000;2892-2897.
25. Horsburgh K., Nicoll J.A. Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Neuropathol Appl Neurobiol. 22:1996;342-349.
26. Knouff C., Hinsdale M.E., Mezdour H., Altenburg M.K., Watanabe M., Quarfordt S.H., Sullivan P.M., Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 103:1999;1579-1586.
27. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 269:1994;23403-23406.
28. Leroy A., Vu-dac N., Koffigan M., Clavey V., Fruchart J.C. Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E applications to ELISA quantification of plasma apo E. J Immunoassay. 9:1988;309-334.
29. Lynch J.R., Pineda J.A., Morgan D., Zhang L., Warner D.S., Benveniste H., Laskowitz D.T. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol. 51:2002;113-117.
30. Mahley R.W. Apolipoprotein E cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
31. Metzger R.E., LaDu M.J., Pan J.B., Getz G.S., Frail D.E., Falduto M.T. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity implications for Alzheimer's disease. J Neuropath Exp Neurol. 55:1996;372-380.
32. Murakami M., Ushio Y., Morino Y., Ohta T., Matsukado Y. Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J Clin Invest. 82:1988;177-188.
33. Nakai M., Kawamata T., Taniguchi T., Maeda K., Tanaka C. Expression of apolipoprotein E mRNA in rat microglia. Neurosci Lett. 211:1996;41-44.
34. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:1991;163-166.
35. Naslund J., Thyberg J., Tjernberg L.O., Wernstedt C., Karistrom A.R., Bogdanovic N., Gandy S.E., Lannfelt L., Terenius L., Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron. 15:1995;219-228.
36. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264:1994;850-852.
37. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 917:1987;148-161.
38. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17:1994;525-530.
39. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
40. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA. 95:1998;10914-10919.
41. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease allelic variation and receptor interactions. Neuron. 11:1993;575-580.
42. Rubinsztein D.C., Easton D.F. Apolipoprotein E genetic variation and Alzheimer's disease, a meta-analysis. Dement Geriatr Cogn Disord. 10:1999;199-209.
43. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
44. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 90:1993;9649-9653.
45. Sheng H., Laskowitz D.T., Mackensen G.B., Kudo M., Pearistein R.D., Warner D.S. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke. 30:1999;1118-1124.
46. Smith J.D. Apolipoproteins and aging emerging mechanisms. Ageing Res Rev. 1:2002;345-365.
47. Smith J.D., Sikes J., Levin J.A. Human apolipoprotein E allele-specific brain expressing transgenic mice. Neurobiol Aging. 19:1998;407-413.
48. Stone D.J., Rozovsky I., Morgan T.E., Anderson C.P., Hajian H., Finch C.E. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 143:1997;313-318.
49. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 90:1993;1977-1981.
50. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M., Jakes R., Huang D.Y., Pericak-Vance M., Schmechel D., Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau implications for Alzheimer disease. Proc Natl Acad Sci USA. 91:1994;11183-11186.
51. Sullivan P.M., Mezdour H., Quarfordt S.H., Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 102:1998;130-135.
52. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 272:1997;17972-17980.
53. Sun Y., Wu S., Bu G., Onifade M.K., Patel S.N., LaDu M.J., Fagan A.M., Holtzman D.M. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 18:1998;3261-3272.
54. Tesseur I., Van Dorpe J., Bruynseels K., Bronfman F., Sciot R., Van Lommel A., Van Leuven F. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol. 157:2000;1495-1510.
55. Teter B., Xu P.T., Gilbert J.R., Roses A.D., Galasko D., Cole G.M. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J Neurochem. 73:1999;2613-2616.
56. van den Maagdenberg A.M., Hofker M.H., Krimpenfort P.J., de Bruijn I., van Vlijmen B., van der Boom H., Havekes L.M., Frants R.R. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 268:1993;10540-10545.
57. Weisgraber K.H., Shinto L.H. identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma impact on receptor binding activity. J Biol Chem. 266:1991;12029-12034.
58. Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 257:1982;2518-2521.
59. White F., Nicoll J.A., Roses A.D., Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis. 8:2001;611-625.
60. Wisniewski T., Frangione B. Apolipoprotein E a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 135:1992;235-238.
61. Xu P.T., Gilbert J.R., Qiu H.L., Ervin J., Rothrock-Christian T.R., Hulette C., Schmechel D.E. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol. 154:1999;601-611.
62. Xu P.T., Schmechel D., Rothrock-Christian T., Burkhart D.S., Qiu H.L., Popko B., Sullivan P., Maeda N., Saunders A.M., Roses A.D., Gilbert J.R. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis. 3:1996;229-245.
63. Zarow C., Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol. 149:1998;79-86.